Literature DB >> 1670787

Feasibility of reversing benzodiazepine tolerance with flumazenil.

I Savic1, L Widén, S Stone-Elander.   

Abstract

To examine whether the benzodiazepine antagonist flumazenil can reverse tolerance to benzodiazepines but without precipitating withdrawal seizures, the antiepileptic effect of flumazenil itself and its ability to reverse tolerance at a dose that would leave sufficient receptors free for the binding of benzodiazepines were investigated. Electroencephalographic studies in 6 patients with partial and 6 with generalised seizures showed that flumazenil had a short (20 min) non-dose-dependent suppressant effect on epileptic discharges in those with partial seizures. Receptor occupancy studies in 12 patients showed that 1.5 mg flumazenil given intravenously occupied 55% receptors, whereas 15 mg occupied nearly all receptors. When 3 patients with partial seizures who had become tolerant to clonazepam were given 1.5 mg flumazenil, they were seizure-free for 6-21 days after the injection. The value of intermittent therapy with a benzodiazepine antagonist for preventing or reversing tolerance to benzodiazepine agonists ought to be investigated further.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1670787     DOI: 10.1016/0140-6736(91)90799-u

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  15 in total

Review 1.  Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users.

Authors:  D I Quinn; A Wodak; R O Day
Journal:  Clin Pharmacokinet       Date:  1997-11       Impact factor: 6.447

2.  Women with PTSD have a changed sensitivity to GABA-A receptor active substances.

Authors:  Anna Tiihonen Möller; Torbjörn Bäckström; Sigrid Nyberg; Hans Peter Söndergaard; Lotti Helström
Journal:  Psychopharmacology (Berl)       Date:  2014-10-28       Impact factor: 4.530

3.  Precipitated withdrawal in squirrel monkeys after repeated daily oral administration of alprazolam, diazepam, flunitrazepam or oxazepam.

Authors:  J R Martin; J L Moreau; F Jenck
Journal:  Psychopharmacology (Berl)       Date:  1995-04       Impact factor: 4.530

4.  Pharmacological characterization of benzodiazepine receptor ligands with intrinsic efficacies ranging from high to zero.

Authors:  J R Martin; P Schoch; F Jenck; J L Moreau; W E Haefely
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

5.  Women with premenstrual dysphoric disorder have altered sensitivity to allopregnanolone over the menstrual cycle compared to controls-a pilot study.

Authors:  Erika Timby; Torbjörn Bäckström; Sigrid Nyberg; Hans Stenlund; Anna-Carin N Wihlbäck; Marie Bixo
Journal:  Psychopharmacology (Berl)       Date:  2016-03-10       Impact factor: 4.530

6.  Peripheral benzodiazepine receptors in platelets of epileptic patients.

Authors:  J G Larkin; P J McKee; G G Thompson; M J Brodie
Journal:  Br J Clin Pharmacol       Date:  1993-07       Impact factor: 4.335

7.  Flumazenil-precipitated withdrawal in healthy volunteers following repeated diazepam exposure.

Authors:  Miriam Z Mintzer; Roland R Griffiths
Journal:  Psychopharmacology (Berl)       Date:  2004-09-25       Impact factor: 4.530

8.  The plasma-occupancy relationship of the novel GABAA receptor benzodiazepine site ligand, alpha5IA, is similar in rats and primates.

Authors:  John R Atack; Wai-Si Eng; Ray E Gibson; Christine Ryan; Barbara Francis; Bindi Sohal; Gerard R Dawson; Richard J Hargreaves; H Donald Burns
Journal:  Br J Pharmacol       Date:  2009-04-30       Impact factor: 8.739

9.  In vivo demonstration of altered benzodiazepine receptor density in patients with generalised epilepsy.

Authors:  I Savic; S Pauli; J O Thorell; G Blomqvist
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-07       Impact factor: 10.154

10.  Functional integrity of benzodiazepine receptors of the geniculo-striate visual pathways in Creutzfeldt-Jakob disease. A pharmacological evoked potential study.

Authors:  U Aguglia; R L Oliveri; A Gambardella; A Quattrone
Journal:  J Neurol       Date:  1993-01       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.